CCL18 and ovarian cancer: Li et al. found that CXCL13 combined with CCL18, HLA-DOB, HLA-DPB2, and TNFRSF17 is associated with better overall survival in ovarian cancer between high and low abundance immune subtypes (Li et al., 2021).